Pharmaceutical

Ocaliva approval in Europe withdrawn following data re-assessment

Advanz Pharma, Ocaliva’s manufacturer, said thousands of patients will no longer benefit from the treatment.

Sep 4, 2024 - 04:00
Ocaliva approval in Europe withdrawn following data re-assessment
Advanz Pharma, Ocaliva’s manufacturer, said thousands of patients will no longer benefit from the treatment.
Read the original article

Tags:

Previous Article

RegenxBio touts positive data for rare disease drug RGX-121

Next Article

Skyline wins orphan drug designation for retinitis pigmentosa gene therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease

Eli Lilly’s donanemab wins FDA approval for Alzheimer’s...

Jul 4, 2024

What makes a drug a blockbuster — or a cautionary tale?

What makes a drug a blockbuster — or a cautionary tale?

Feb 3, 2024

STAT+: ViiV Healthcare and Doctors Without Borders tussle over contract terms for an HIV drug

STAT+: ViiV Healthcare and Doctors Without Borders tuss...

Aug 17, 2023